Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]
In development [GID-TA10277] Expected publication date: TBC
Search results
583 results
-
-
Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347
In development [GID-TA10264] Expected publication date: TBC
-
Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270
In development [GID-TA10211] Expected publication date: TBC
-
Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]
In development [GID-TA10634] Expected publication date: TBC
-
Guadecitabine for untreated acute myeloid leukaemia ID1411
In development [GID-TA10325] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]
In development [GID-TA10234] Expected publication date: TBC
-
Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]
In development [GID-TA10341] Expected publication date: TBC
-
Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495
In development [GID-TA10395] Expected publication date: TBC
-
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
In development [GID-TA10380] Expected publication date: TBC
-
Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
In development [GID-TA10494] Expected publication date: TBC
-
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
In development [GID-TA10480] Expected publication date: TBC
-
Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264
In development [GID-TA10365] Expected publication date: TBC
-
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
In development [GID-TA10158] Expected publication date: TBC
-
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (ID1375)
In development [GID-TA10360] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
In development [GID-TA10295] Expected publication date: TBC
-
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
In development [GID-TA10390] Expected publication date: TBC
-
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
In development [GID-TA10546] Expected publication date: TBC
-
Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331
In development [GID-TA10318] Expected publication date: TBC
-
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
In development [GID-TA10221] Expected publication date: TBC
-
Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]
In development [GID-TAG431] Expected publication date: TBC
-
Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]
In development [GID-TAG425] Expected publication date: TBC
-
Pulmonary arterial hypertension (adults) - drugs [ID12]
In development [GID-TAG382] Expected publication date: TBC
-
Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]
In development [GID-TAG444] Expected publication date: TBC
-
Breast cancer - intensity modulated radiotherapy [ID16]
In development [GID-TAG390] Expected publication date: TBC
-
Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]
In development [GID-TAG393] Expected publication date: TBC
-
Hypercholesterolemia - mipomersen [ID524]
In development [GID-TAG437] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) - lapatinib [ID20]
In development [GID-TAG387] Expected publication date: TBC
-
T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]
In development [GID-TAG433] Expected publication date: TBC
-
Thrombophilia [ID393]
In development [GID-TAG374] Expected publication date: TBC
-
Systemic lupus erythematosus - prasterone [ID392]
In development [GID-TAG373] Expected publication date: TBC
-
Falls - faller's clinics [ID103]
In development [GID-TAG375] Expected publication date: TBC
-
Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]
In development [GID-TAG436] Expected publication date: TBC
-
Lung cancer (non-small-cell) - cetuximab [ID9]
In development [GID-TAG395] Expected publication date: TBC
-
Venous thromboembolism (prevention) - rivaroxaban [ID463]
In development [GID-TAG427] Expected publication date: TBC
-
Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]
In development [GID-TAG337] Expected publication date: TBC
-
Heart failure (acute) - serelaxin [ID673]
In development [GID-TAG454] Expected publication date: TBC
-
Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]
In development [GID-TAG332] Expected publication date: TBC
-
Macular oedema (diabetic) - pegaptanib sodium [ID452]
In development [GID-TAG280] Expected publication date: TBC
-
Venous thromboembolism - apixaban (acute medical illness) [ID310]
In development [GID-TAG419] Expected publication date: TBC
-
Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]
In development [GID-TAG417] Expected publication date: TBC
-
Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]
In development [GID-TAG404] Expected publication date: TBC
-
Lung cancer (non-small-cell, untreated) - paclitaxel formulated as albumin-bound nanoparticles (with carboplatin) [ID553]
In development [GID-TAG528] Expected publication date: TBC
-
Juvenile idiopathic arthritis - abatacept [ID27]
In development [GID-TAG402] Expected publication date: TBC
-
Glioblastoma - bevacizumab [ID80]
In development [GID-TAG413] Expected publication date: TBC
-
Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622
In development [GID-TAG360] Expected publication date: TBC
-
Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]
In development [GID-TAG424] Expected publication date: TBC
-
Multiple myeloma - bortezomib (consolidation therapy) [ID529]
In development [GID-TAG320] Expected publication date: TBC
-
Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]
In development [GID-TAG435] Expected publication date: TBC
-
Generalised anxiety disorder - quetiapine [ID347]
In development [GID-TAG421] Expected publication date: TBC
-
Pancreatic cancer - capecitabine [ID389]
In development [GID-TAG394] Expected publication date: TBC